spacer
home > ebr > spring 2019 > the authenticity of synthetics
PUBLICATIONS
European Biopharmaceutical Review

The Authenticity of Synthetics

Synthetic biology is a newly coined term for the design and construction of novel artificial biological pathways, organisms, or devices or the redesign of existing natural biological systems (1). Generally, it assumes an element of scale and the application of engineering-like techniques to solve biological problems through a rational process of ‘biodesign’. The field of synthetic biology brings together skills from biology and chemistry to computing, bioinformatics, and engineering. This emerging field is greatly anticipated to deliver significant and broad impact across a range of potential applications, among them the drug discovery and development field. However, to achieve its full potential, synthetic biology will require the continued development and convergence of its underlying skills and disciplines to enable the rational and predictable design of biological systems. As DNA is a fundamental building block of synthetic biology, the key to its success will be the ability to synthesise DNA at scale and with high accuracy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Tim Brears is CEO at Evonetix, where he leads the company in developing a benchtop DNA writer to transition DNA synthesis from a service industry to one where scientists can make genes at will. He holds a PhD from the University of Cambridge, UK, and has an MBA from Duke University’s Fuqua School of Business, US.
spacer
Dr Tim Brears
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

New Temperature Profiles from a Global Study

Laminar Medica

Recently there has been an influx of temperature mapping studies to collect sufficient ambient data to develop temperature profiles.  Solid temperature profiles on specific shipping routes are required to ensure streamlined packaging and robust lane qualification. The most reliable method to develop temperature profiles is to capture the actual reading from shipments, as well as using the historical and meteorological data to increase the confidence level.
More info >>

 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement